Trial Profile
A Phase 1, randomized, double-blind, placebo-controlled, 5 arm, parallel group study of the safety, tolerability and pharmacokinetics of oral BTD-001 in 30 male and female healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Pentylenetetrazole (Primary)
- Indications Cognition disorders; Down syndrome
- Focus Adverse reactions
- 06 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 19 Sep 2013 New trial record